NCT01351935 - Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | Biotech Hunter

Enrollment

113

Participants

Timeline

Start Date

July 18, 2011

Primary Completion Date

June 26, 2015

Study Completion Date

June 26, 2015

Conditions

B Cell Non-Hodgkin's LymphomaChronic Lymphocytic LeukemiaWaldenstrom Macroglobulinemia

Interventions

DRUG

AVL-292

125 mg to 625 mg orally, once a day, for 28 days (28 days equals 1 cycle). Number of cycles: until progression or unacceptable toxicity develops

Trial Locations (13)

Mount Sinai School of Medicine and Mount Sinai Graduate School of Biological Sciences, New York

University of Rochester Medical Center, Rochester

Mayo Clinic Jacksonville, Jacksonville

Clearview Cancer Institute Oncology Specialties, P.C, Huntsville

Cleveland Clinic, Cleveland

Horizon Oncology Center, Lafayette

Northwestern University, Chicago

The University of Texas MD Anderson Cancer Center, Houston

US Oncology, The Woodlands

University of Texas Health Sciences Center, San Antonio

University of Arizona SPORE, Tucson

University of California San Diego, La Jolla

Dana Farber Cancer Institute, Boston